Worldwide, hospital-acquired infections (HAIs) are continuously rising within healthcare settings, leading to high mortality and morbidity rates. Many hospitals have reported the spread of carbapenemases globally, specifically within theE. coliandK. pneumoniaespecies. This study was aimed at analyzing the state of hospital-acquired, carbapenem-resistantE. coliandK. pneumoniaein the United Kingdom between 2009 and 2021. Moreover, the study analyzed the most efficacious approaches to patient management for controlling the carbapenem-resistant Enterobacteriaceae (CRE) spread. Initially, 1094 articles were identified as relevant for screening, and among them, 49 papers were eligible for full-text screening, with a total of 14 articles meeting the inclusion criteria. The information was recorded from published articles through PubMed, the Web of Science, Scopus, Science Direct, and the Cochrane library and was used to search for hospital-acquired carbapenem-resistantE. coliandK pneumoniaein the UK between 2009 and 2021, in order to evaluate the spread of CRE in hospitals. The total number of carbapenem-resistantE. coliwas 1083 and this was 2053 for carbapenem-resistantK. pneumoniaein more than 63 UK hospitals. KPC was the dominant carbapenemase produced byK. pneumoniae. The results showed that the treatment options considered depended on the type of carbapenemase produced;K. pneumoniaeshowed more resistance to a treatment options, i.e., Colistin, than the other carbapenemase. The current state of the UK is at minimal risk for a CRE outbreak; however, appropriate treatment and infection control measures are highly required to prevent this CRE spread at the regional and global levels. The present study findings have an important message for physicians, healthcare workers, and policymakers about hospital-acquired carbapenem-resistantE. coliandK. pneumoniaespread and approaches to patient management.